What is the recommended dose and titration of isoprenaline (isoproterenol) for adult patients?

Isoprenaline Dosing for Adult Patients

For symptomatic bradycardia or shock in adults, initiate isoprenaline at 0.5-5 mcg/min as a continuous IV infusion, starting at the lowest dose and titrating based on heart rate response, with a target heart rate increase that maintains hemodynamic stability while avoiding rates exceeding 110 bpm. 1222

Initial Dosing by Clinical Indication

For Bradycardia/Shock States

• Start: 0.5-5 mcg/min continuous IV infusion 122
• Alternative bolus approach: 20-60 mcg IV bolus followed by 10-20 mcg increments, or switch to infusion of 1-20 mcg/min based on heart rate response 1
• Preparation: Dilute 5 mL (1 mg) in 500 mL of 5% Dextrose (yields 2 mcg/mL solution) 2
• Infusion rate conversion: 0.5 mcg/min = 0.25 mL/min of diluted solution; 5 mcg/min = 2.5 mL/min 2

For Bronchospasm During Anesthesia

• Dose: 10-20 mcg IV bolus injection 122
• Preparation: Dilute 1 mL (0.2 mg) to 10 mL with normal saline or 5% dextrose 2
• Repeat: May repeat initial dose as necessary 2

Titration Strategy

Monitor heart rate continuously and adjust infusion every 2-5 minutes based on response:

• Target a heart rate that improves hemodynamic parameters (blood pressure, urine output, central venous pressure) without excessive tachycardia 1
• Critical threshold: If heart rate exceeds 110 bpm, decrease or temporarily discontinue the infusion 2
• In advanced shock states, rates over 30 mcg/min have been used, though this increases risk of arrhythmias and ischemia 12
• Concentrations up to 10 times greater (20 mcg/mL) may be prepared when volume restriction is essential 2

Key Monitoring Parameters

Continuously assess these endpoints to guide titration:

• Heart rate (primary parameter)
• Blood pressure (systolic and mean arterial pressure)
• Central venous pressure
• Urine output
• ECG for arrhythmias
• Signs of myocardial ischemia (chest pain, ST-segment changes) 12

Critical Safety Considerations

Absolute contraindications - do not use isoprenaline in patients with: 2

• Pre-existing tachycardia
• Ventricular arrhythmias
• Angina pectoris or active coronary ischemia

Major caution: Isoprenaline increases myocardial oxygen consumption through combined chronotropic and inotropic effects. A case report documented acute myocardial infarction precipitated by therapeutic isoprenaline use in a patient with occult coronary disease 3. Exercise extreme caution in patients at risk for coronary artery disease, even without known disease.

Arrhythmia risk: The drug can induce serious cardiac arrhythmias and ischemia, particularly at higher doses or in susceptible patients 12. Research demonstrates that the AV node is more sensitive than the sinus node to isoprenaline effects, meaning lower doses may suffice for improving AV conduction while minimizing side effects 4.

Special Populations

Pediatric Dosing

• Initial rate: 0.1 mcg/kg/min IV infusion 2
• Usual range: 0.1-1 mcg/kg/min 2
• Note: No well-controlled pediatric studies exist; this represents American Heart Association consensus recommendations

Patients with Suspected Coronary Disease

Given the documented case of isoprenaline-induced myocardial infarction 3, use the absolute lowest effective dose in patients with cardiovascular risk factors. Consider alternative agents (dopamine, epinephrine) if coronary disease is suspected, as recommended by ACC/AHA/HRS guidelines for patients at high likelihood of coronary ischemia 1.

Practical Dosing Algorithm

1. Verify no contraindications (tachycardia, ventricular arrhythmias, angina)
2. Prepare infusion: 1 mg in 500 mL D5W (standard concentration)
3. Start at 0.5 mcg/min (0.25 mL/min of diluted solution)
4. Increase by 0.5-1 mcg/min every 2-5 minutes until:
   • Heart rate improves to 60-100 bpm, OR
   • Hemodynamic parameters stabilize, OR
   • Heart rate reaches 110 bpm (stop and reassess)
5. Maximum typical dose: 5 mcg/min for initial management
6. Advanced shock: May increase to 30+ mcg/min if needed, with heightened vigilance for complications

Drug Interactions

Do not administer simultaneously with epinephrine - combined effects may induce serious arrhythmias 2. Allow adequate washout period between agents.

Potentiation of effects occurs with: 2

• Tricyclic antidepressants
• MAO inhibitors
• Levothyroxine
• Certain antihistamines

Antagonism by beta-adrenergic blocking drugs reduces both cardiostimulating and bronchodilating effects 2.

Sulfite Allergy Warning

Isoprenaline contains metabisulfite, which may cause allergic-type reactions including anaphylaxis in susceptible individuals, particularly those with asthma 22. Screen for sulfite sensitivity before administration.